Moderna (NASDAQ: MRNA) has recently received a number of price target changes and ratings updates:
- 9/19/2024 – Moderna had its “sector perform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $75.00 price target on the stock.
- 9/17/2024 – Moderna had its price target lowered by analysts at Leerink Partners from $60.00 to $48.00. They now have an “underperform” rating on the stock.
- 9/16/2024 – Moderna had its price target lowered by analysts at Barclays PLC from $155.00 to $125.00. They now have an “overweight” rating on the stock.
- 9/16/2024 – Moderna had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $178.00 to $139.00. They now have a “buy” rating on the stock.
- 9/13/2024 – Moderna was downgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “underweight” rating. They now have a $70.00 price target on the stock, down previously from $88.00.
- 9/13/2024 – Moderna had its price target lowered by analysts at Royal Bank of Canada from $90.00 to $75.00. They now have a “sector perform” rating on the stock.
- 9/13/2024 – Moderna had its price target lowered by analysts at Piper Sandler from $157.00 to $115.00. They now have an “overweight” rating on the stock.
- 9/13/2024 – Moderna had its price target lowered by analysts at Bank of America Co. from $130.00 to $110.00. They now have a “neutral” rating on the stock.
- 9/13/2024 – Moderna was downgraded by analysts at Oppenheimer Holdings Inc. from an “outperform” rating to a “market perform” rating.
- 9/13/2024 – Moderna had its price target lowered by analysts at TD Cowen from $70.00 to $60.00. They now have a “hold” rating on the stock.
- 9/13/2024 – Moderna had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
- 9/13/2024 – Moderna was downgraded by analysts at Jefferies Financial Group Inc. from a “buy” rating to a “hold” rating. They now have a $65.00 price target on the stock, down previously from $120.00.
- 8/28/2024 – Moderna was upgraded by analysts at Hsbc Global Res from a “moderate sell” rating to a “hold” rating.
- 8/28/2024 – Moderna was upgraded by analysts at HSBC Holdings plc from a “reduce” rating to a “hold” rating. They now have a $82.00 price target on the stock.
- 8/15/2024 – Moderna had its price target lowered by analysts at JPMorgan Chase & Co. from $96.00 to $88.00. They now have a “neutral” rating on the stock.
- 8/7/2024 – Moderna was upgraded by analysts at Deutsche Bank Aktiengesellschaft from a “sell” rating to a “hold” rating. They now have a $80.00 price target on the stock, down previously from $85.00.
- 8/5/2024 – Moderna was downgraded by analysts at Royal Bank of Canada from an “outperform” rating to a “sector perform” rating. They now have a $90.00 price target on the stock, down previously from $125.00.
- 8/2/2024 – Moderna had its price target lowered by analysts at Barclays PLC from $168.00 to $155.00. They now have an “overweight” rating on the stock.
- 8/2/2024 – Moderna had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $157.00 price target on the stock, down previously from $214.00.
- 8/2/2024 – Moderna had its price target lowered by analysts at Royal Bank of Canada from $160.00 to $125.00. They now have an “outperform” rating on the stock.
- 8/2/2024 – Moderna had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $204.00 to $178.00. They now have a “buy” rating on the stock.
- 8/1/2024 – Moderna had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
Moderna Stock Up 3.6 %
NASDAQ:MRNA traded up $2.30 during midday trading on Friday, reaching $66.23. 2,554,483 shares of the stock traded hands, compared to its average volume of 4,310,323. The business has a 50-day moving average of $85.34 and a two-hundred day moving average of $109.78. The stock has a market capitalization of $25.38 billion, a PE ratio of -4.23 and a beta of 1.67. Moderna, Inc. has a 12-month low of $62.55 and a 12-month high of $170.47. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09.
Moderna (NASDAQ:MRNA – Get Free Report) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The business had revenue of $241.00 million during the quarter, compared to analysts’ expectations of $128.41 million. During the same quarter last year, the company posted ($3.62) earnings per share. The business’s quarterly revenue was down 29.9% on a year-over-year basis. On average, equities analysts forecast that Moderna, Inc. will post -9.86 earnings per share for the current fiscal year.
Insider Activity at Moderna
Institutional Trading of Moderna
Several institutional investors have recently modified their holdings of MRNA. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Moderna in the second quarter valued at about $26,000. Cedar Wealth Management LLC lifted its stake in shares of Moderna by 45.0% in the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after buying an additional 90 shares in the last quarter. Westside Investment Management Inc. purchased a new position in shares of Moderna in the first quarter worth about $32,000. Family Firm Inc. purchased a new position in shares of Moderna in the second quarter worth about $33,000. Finally, Rise Advisors LLC lifted its stake in shares of Moderna by 953.3% in the first quarter. Rise Advisors LLC now owns 316 shares of the company’s stock worth $34,000 after buying an additional 286 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Featured Articles
- Five stocks we like better than Moderna
- Dividend Payout Ratio Calculator
- These 3 Stocks Show How to Navigate Declining Consumer Confidence
- What is the NASDAQ Stock Exchange?
- MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy?
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- What Intuitive Machines’ Big NASA Contract Means for Investors
Receive News & Ratings for Moderna Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna Inc and related companies with MarketBeat.com's FREE daily email newsletter.